文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

深度生成式 AI 模型分析循环孤儿非编码 RNA 可实现早期肺癌检测。

Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer.

机构信息

Exai Bio Inc., Palo Alto, CA, US.

Weill Cornell Medicine, New York, NY, US.

出版信息

Nat Commun. 2024 Nov 21;15(1):10090. doi: 10.1038/s41467-024-53851-9.


DOI:10.1038/s41467-024-53851-9
PMID:39572521
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11582319/
Abstract

Liquid biopsies have the potential to revolutionize cancer care through non-invasive early detection of tumors. Developing a robust liquid biopsy test requires collecting high-dimensional data from a large number of blood samples across heterogeneous groups of patients. We propose that the generative capability of variational auto-encoders enables learning a robust and generalizable signature of blood-based biomarkers. In this study, we analyze orphan non-coding RNAs (oncRNAs) from serum samples of 1050 individuals diagnosed with non-small cell lung cancer (NSCLC) at various stages, as well as sex-, age-, and BMI-matched controls. We demonstrate that our multi-task generative AI model, Orion, surpasses commonly used methods in both overall performance and generalizability to held-out datasets. Orion achieves an overall sensitivity of 94% (95% CI: 87%-98%) at 87% (95% CI: 81%-93%) specificity for cancer detection across all stages, outperforming the sensitivity of other methods on held-out validation datasets by more than  ~ 30%.

摘要

液体活检有可能通过非侵入性的肿瘤早期检测来改变癌症治疗方式。开发一种稳健的液体活检测试需要从大量不同异质性患者群体的血液样本中收集高维数据。我们提出变分自动编码器的生成能力能够学习基于血液的生物标志物的稳健且可推广的特征。在这项研究中,我们分析了来自 1050 名被诊断患有非小细胞肺癌(NSCLC)的个体的血清样本中的孤儿非编码 RNA(oncRNA),以及性别、年龄和 BMI 匹配的对照。我们证明了我们的多任务生成式 AI 模型 Orion 在整体性能和对保留数据集的泛化能力方面均超过了常用方法。Orion 在所有阶段的癌症检测中达到了 94%(95%CI:87%-98%)的整体敏感性和 87%(95%CI:81%-93%)的特异性,在保留验证数据集上的敏感性超过其他方法 30%以上。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cf/11582319/7782475721d8/41467_2024_53851_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cf/11582319/c7295b876941/41467_2024_53851_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cf/11582319/4c6f3175fc76/41467_2024_53851_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cf/11582319/58a29262b052/41467_2024_53851_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cf/11582319/7782475721d8/41467_2024_53851_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cf/11582319/c7295b876941/41467_2024_53851_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cf/11582319/4c6f3175fc76/41467_2024_53851_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cf/11582319/58a29262b052/41467_2024_53851_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6cf/11582319/7782475721d8/41467_2024_53851_Fig4_HTML.jpg

相似文献

[1]
Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early-stage lung cancer.

Nat Commun. 2024-11-21

[2]
Single tube liquid biopsy for advanced non-small cell lung cancer.

Int J Cancer. 2019-1-28

[3]
miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.

J Thorac Oncol. 2011-3

[4]
Serum lipidomic biomarkers for non-small cell lung cancer in nonsmoking female patients.

J Pharm Biomed Anal. 2020-6-5

[5]
Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer.

Transl Res. 2024-10

[6]
Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer.

Ann Oncol. 2018-12-1

[7]
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.

Cancer. 2024-5-15

[8]
Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer.

J Egypt Natl Canc Inst. 2024-6-17

[9]
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.

Oncotarget. 2016-10-11

[10]
Identification of ncRNA Biomarkers in Non-Small Cell Lung Cancer to Address Racial Disparities.

Cancer Res Commun. 2024-12-1

引用本文的文献

[1]
DDX27 in cancer: molecular mechanisms, clinical implications, and therapeutic potential.

J Transl Med. 2025-8-28

[2]
Advancements in DNA methylation technologies and their application in cancer diagnosis.

Epigenetics. 2025-12

[3]
Advances in molecular pathology and therapy of non-small cell lung cancer.

Signal Transduct Target Ther. 2025-6-15

[4]
Liquid Biopsy: The Challenges of a Revolutionary Approach in Oncology.

Int J Mol Sci. 2025-5-23

[5]
Current AI technologies in cancer diagnostics and treatment.

Mol Cancer. 2025-6-2

[6]
Long noncoding RNAs in familial hypercholesterolemia: biomarkers, therapeutics, and AI in precision medicine.

Lipids Health Dis. 2025-5-21

[7]
Development and validation of machine learning models based on molecular features for estimating the probability of multiple primary lung carcinoma versus intrapulmonary metastasis in patients presenting multiple non-small cell lung cancers.

Transl Lung Cancer Res. 2025-4-30

[8]
Detection of Early-Stage Colorectal Cancer Using Cell-Free oncRNA Biomarkers and Artificial Intelligence.

Clin Cancer Res. 2025-8-1

[9]
An ultrasensitive method for detection of cell-free RNA.

Nature. 2025-5

[10]
New Perspectives on Lung Cancer Screening and Artificial Intelligence.

Life (Basel). 2025-3-19

本文引用的文献

[1]
Clinical Utility of Tumor-Naïve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC.

J Thorac Oncol. 2024-11

[2]
Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection.

Cancer Discov. 2024-11-1

[3]
scGPT: toward building a foundation model for single-cell multi-omics using generative AI.

Nat Methods. 2024-8

[4]
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.

Cancer Cell. 2024-3-11

[5]
Toward universal cell embeddings: integrating single-cell RNA-seq datasets across species with SATURN.

Nat Methods. 2024-8

[6]
Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study.

Lancet. 2023-10-7

[7]
ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy.

Front Oncol. 2023-9-19

[8]
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.

Cancer Discov. 2023-11-1

[9]
Isolating salient variations of interest in single-cell data with contrastiveVI.

Nat Methods. 2023-9

[10]
Long non-coding RNA SOX2-OT enhances cancer biological traits via sponging to tumor suppressor miR-122-3p and miR-194-5p in non-small cell lung carcinoma.

Sci Rep. 2023-7-31

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索